Papers

Peer-reviewed
May, 2017

Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population

HEART AND VESSELS
  • Fumihiko Kitagawa
  • Junnichi Ishii
  • Shinya Hiramitsu
  • Hiroshi Takahashi
  • Ryuunosuke Okuyama
  • Hideki Kawai
  • Takashi Muramatsu
  • Masahide Harada
  • Sadako Motoyama
  • Hiroyuki Naruse
  • Shigeru Matsui
  • Masayoshi Sarai
  • Mutsuharu Hayashi
  • Eiichi Watanabe
  • Hideo Izawa
  • Yukio Ozaki
  • Display all

Volume
32
Number
5
First page
609
Last page
617
Language
English
Publishing type
Research paper (scientific journal)
DOI
10.1007/s00380-016-0912-0
Publisher
SPRINGER

Whether trough-phase rivaroxaban concentrations provide sufficient anticoagulation needs more study. We evaluated levels of coagulation activation markers in the trough concentration phase in nonvalvular atrial fibrillation (NVAF) patients, and the correlation between these markers and rivaroxaban concentration. Fifty-five Japanese NVAF patients received 24-week rivaroxaban treatment of either 15 or 10 mg once-daily in the morning. Of these, 26 patients had no history of anticoagulant therapy (naive group) and 29 had switched from warfarin (warfarin group). D-dimer and prothrombin fragment 1 + 2 (F1 + 2) levels, and protein C activities were measured at 0 (baseline), 12 and 24 weeks of rivaroxaban treatment just before the patient's regular dosing time (trough phase). For 49 patients, D-dimer, F1 + 2, and rivaroxaban concentrations were also measured twice between 28 and 32 weeks of rivaroxaban treatment at non-trough times to achieve a range of drug concentrations for correlation analysis. For the naive group, D-dimer and F1 + 2 levels were significantly reduced (p < 0.01) from baseline at 12 and 24 weeks. For the warfarin group, these values were unchanged for D-dimer but significantly increased (p < 0.01) for F1 + 2. Protein C activity was unchanged in the naive group and was increased (p < 0.01) in the warfarin group. Prothrombin time (r = 0.92, p < 0.0001) and activated partial thromboplastin time (r = 0.54, p < 0.0001) correlated with rivaroxaban concentration, but not D-dimer and F1 + 2 levels. In conclusion, rivaroxaban in the trough phase is comparable to warfarin in reducing D-dimer levels. Although trough level rivaroxaban suppresses F1 + 2 less than warfarin, the higher activities of protein C with rivaroxaban treatment compared to warfarin treatment may counterbalance this. Lack of correlation between rivaroxaban concentration and D-dimer and F1 + 2 levels suggests that trough concentrations of rivaroxaban reduce their concentrations as effectively as higher levels do.

Link information
DOI
https://doi.org/10.1007/s00380-016-0912-0
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/27796530
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000402144000013&DestApp=WOS_CPL
ID information
  • DOI : 10.1007/s00380-016-0912-0
  • ISSN : 0910-8327
  • eISSN : 1615-2573
  • Pubmed ID : 27796530
  • Web of Science ID : WOS:000402144000013

Export
BibTeX RIS